文献速递中毒与环境急症消化、代谢与肾脏急症

马萨诸塞州监禁期间及释放时使用与不使用阿片使用障碍药物治疗的估计成本与结局

Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论模拟模型提示:对监禁期间阿片使用障碍者提供全部3种药物(纳曲酮、丁丙诺啡、美沙酮)较仅释放时提供缓释纳曲酮可预防更多过量死亡且节省费用。

该经济评估采用模拟建模与成本效果分析,成本和质量调整生命年(QALY)按3%贴现,比较马萨诸塞州惩教队列和开放队列中阿片使用障碍(OUD)者的三种策略:不提供药物、仅释放时提供缓释纳曲酮、入监时提供全部3种药物。在3万名模拟监禁OUD者中,不提供药物5年内有40927次治疗启动和1259例过量死亡;仅释放时提供缓释纳曲酮额外治疗启动10466次、减少过量死亡40例、每人增加0.08 QALY、增量成本2723美元;入监时提供全部3种药物额外治疗启动11923次、减少过量死亡83例、每人增加0.12 QALY、增量成本852美元。仅缓释纳曲酮策略为劣势策略,全部3种药物相比不提供药物的ICER为每QALY 7252美元;全州范围内仅缓释纳曲酮策略5年避免95例过量死亡(州级死亡率下降0.9%),全部药物策略避免192例(下降1.8%)。作者认为,对监禁OUD者提供任何药物均可预防过量死亡,提供全部3种药物较仅缓释纳曲酮策略预防更多死亡并节省费用。

要点

  • 在3万名模拟监禁OUD者中,不提供药物5年内有40927次(95% UI 39001-42082)治疗启动和1259例(95% UI 1130-1323)过量死亡。
  • 仅释放时提供缓释纳曲酮较不提供药物额外治疗启动10466次(95% UI 8515-12201)、减少过量死亡40例(95% UI 16-50)、每人增加0.08 QALY(95% UI 0.05-0.11),增量成本每人2723美元(95% UI 141-5244)。
  • 入监时提供全部3种药物较不提供药物额外治疗启动11923次(95% UI 10861-12911)、减少过量死亡83例(95% UI 72-91)、每人增加0.12 QALY(95% UI 0.10-0.17),增量成本每人852美元(95% UI 14-1703)。
  • 仅缓释纳曲酮策略为劣势策略(效果更差且成本更高),全部3种药物相比不提供药物的ICER为每QALY 7252美元(95% UI 140-10018)。
  • 全州OUD人群中,仅缓释纳曲酮策略5年避免95例过量死亡(95% UI 85-169),州级死亡率下降0.9%;全部药物策略避免192例(95% UI 156-200),下降1.8%。

适用人群与场景

  • 马萨诸塞州惩教队列中模拟的3万名监禁OUD者。
  • 开放队列代表马萨诸塞州全部OUD个体。

处置流程与药物剂量

  • 策略1:监禁期间及释放时不提供OUD药物。
  • 策略2:仅在释放时提供缓释纳曲酮。
  • 策略3:入监时提供全部3种OUD药物(纳曲酮、丁丙诺啡、美沙酮)。

研究设计与关键结果

  • 研究类型:经济评估,采用模拟建模与成本效果分析,成本和质量调整生命年(QALY)按3%贴现;数据于2021年7月1日至2022年9月30日分析。
  • 在3万名模拟监禁OUD者中,不提供药物5年内有40927次(95% UI 39001-42082)治疗启动和1259例(95% UI 1130-1323)过量死亡。
  • 仅释放时提供缓释纳曲酮较不提供药物额外治疗启动10466次(95% UI 8515-12201)、减少过量死亡40例(95% UI 16-50)、每人增加0.08 QALY(95% UI 0.05-0.11),增量成本每人2723美元(95% UI 141-5244)。
  • 入监时提供全部3种药物较不提供药物额外治疗启动11923次(95% UI 10861-12911)、减少过量死亡83例(95% UI 72-91)、每人增加0.12 QALY(95% UI 0.10-0.17),增量成本每人852美元(95% UI 14-1703)。
  • 仅缓释纳曲酮策略为劣势策略(效果更差且成本更高),全部3种药物相比不提供药物的ICER为每QALY 7252美元(95% UI 140-10018)。
  • 全州OUD人群中,仅缓释纳曲酮策略5年避免95例过量死亡(95% UI 85-169),州级死亡率下降0.9%;全部药物策略避免192例(95% UI 156-200),下降1.8%。

证据类型、等级与局限

  • 证据类型:经济评估(模拟建模与成本效果分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对监禁OUD者提供任何OUD药物均可预防过量死亡。
  • 作者认为,提供全部3种药物较仅缓释纳曲酮策略预防更多死亡并节省费用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Most prisons and jails in the US discontinue medications for opioid use disorder (MOUD) upon incarceration and do not initiate MOUD prior to release.

OBJECTIVE: To model the association of MOUD access during incarceration and at release with population-level overdose mortality and OUD-related treatment costs in Massachusetts.

DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation used simulation modeling and cost-effectiveness with costs and quality-adjusted life-years (QALYs) discounted at 3% to compare MOUD treatment strategies in a corrections cohort and an open cohort representing individuals with OUD in Massachusetts. Data were analyzed between July 1, 2021, and September 30, 2022.

EXPOSURES: Three strategies were compared: (1) no MOUD provided during incarceration or at release, (2) extended-release (XR) naltrexone offered only at release from incarceration, and (3) all 3 MOUDs (naltrexone, buprenorphine, and methadone) offered at intake.

MAIN OUTCOMES AND MEASURES: Treatment starts and retention, fatal overdoses, life-years and QALYs, costs, and incremental cost-effectiveness ratios (ICERs).

RESULTS: Among 30 000 simulated incarcerated individuals with OUD, offering no MOUD was associated with 40 927 (95% uncertainty interval [UI], 39 001-42 082) MOUD treatment starts over a 5-year period and 1259 (95% UI, 1130-1323) overdose deaths after 5 years. Over 5 years, offering XR-naltrexone at release led to 10 466 (95% UI, 8515-12 201) additional treatment starts, 40 (95% UI, 16-50) fewer overdose deaths, and 0.08 (95% UI, 0.05-0.11) QALYs gained per person, at an incremental cost of $2723 (95% UI, $141-$5244) per person. In comparison, offering all 3 MOUDs at intake led to 11 923 (95% UI, 10 861-12 911) additional treatment starts, compared with offering no MOUD, 83 (95% UI, 72-91) fewer overdose deaths, and 0.12 (95% UI, 0.10-0.17) QALYs per person gained, at an incremental cost of $852 (95% UI, $14-$1703) per person. Thus, XR-naltrexone only was a dominated strategy (both less effective and more costly) and the ICER of all 3 MOUDs compared with no MOUD was $7252 (95% UI, $140-$10 018) per QALY. Among everyone with OUD in Massachusetts, XR-naltrexone only averted 95 overdose deaths over 5 years (95% UI, 85-169)-a 0.9% decrease in state-level overdose mortality-while the all-MOUD strategy averted 192 overdose deaths (95% UI, 156-200)-a 1.8% decrease.

CONCLUSIONS AND RELEVANCE: The findings of this simulation-modeling economic study suggest that offering any MOUD to incarcerated individuals with OUD would prevent overdose deaths and that offering all 3 MOUDs would prevent more deaths and save money compared with an XR-naltrexone-only strategy.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Chatterjee A, Weitz M, Savinkina A, et al. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Netw Open. 2023. PMID: 37058306. doi:10.1001/jamanetworkopen.2023.7036

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。